Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyMutual of Omaha Onychomycosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMutual of OmahaPolicy AHS-M2172

    Onychomycosis Testing

    Customize your policy alerts

    Sign up for mutualofomaha Policy AHS-M2172 alerts

    Get alerted when Policy AHS-M2172 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of laboratory tests used to screen for, diagnose, confirm, or further characterize onychomycosis. Coverage criteria apply based on the individual's benefit coverage at the time of request.

    Policy Summary
    PayerMutual of Omaha
    PolicyOnychomycosis Testing
    Policy CodePolicy N/A
    Change TypeNon-material evidence update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionConfirm suspected onychomycosis with appropriate laboratory testing before initiating treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    Conventional testing methods covered
    1NAAT covered after failed antifungal therapy
    3Testing approaches not covered
    50%Nail disease cases attributed to onychomycosis
    95%PAS biopsy sensitivity

    Coverage Criteria

    Conventional Diagnostic Testing

    For individuals with signs of onychomycosis, conventional diagnostic testing meets coverage criteria when at least one of the following methods is performed:

    ONE of the following

    • Direct microscopic examination with potassium hydroxide (KOH).
    • Fungal culture of desquamated subungual material.
    • Fungal stain of nail clipping(s).

    NAAT After Failed Antifungal Therapy

    Nucleic acid amplification testing (NAAT) meets coverage criteria only when ALL of the following requirements are met:

    ALL of the following

    • The individual has onychomycosis.
    • Antifungal therapy has failed to resolve the infection.

    NAAT for Screening or Initial Diagnosis

    NAAT does not meet coverage criteria for any of the following uses:

    Any of the following uses

    • Screening for onychomycosis.
    • Initial diagnosis of onychomycosis.
    • Confirming onychomycosis outside the covered failed-antifungal-therapy indication.

    Unproven or Noncovered Testing Methods

    The following testing methods do not meet coverage criteria because published scientific literature is insufficient to confirm that they are required and beneficial for diagnosing or treating the individual's illness:

    Any of the following methods

    • Attenuated total-reflectance Fourier transform infrared (ATR-FTIR) spectroscopy used to screen for, diagnose, or confirm onychomycosis.
    • Testing for the presence of fungal-derived sterols, including ergosterol.

    Confirmatory Testing for Suspected Onychomycosis

    For suspected onychomycosis, guideline-based recommendations support confirmatory laboratory testing before treatment when clinically appropriate.

    Guideline-based confirmatory testing

    • Obtain laboratory confirmation of suspected nail infection before initiating treatment, when feasible, to distinguish onychomycosis from nonfungal dermatologic conditions, identify mixed infections, and detect less responsive forms of infection.
    • Use one or more of the following confirmatory methods

      • Potassium hydroxide (KOH) preparation with direct microscopic examination; KOH is described as the preferred, rapid, specific, and cost-effective method, and a positive result may be sufficient to initiate treatment.
      • Periodic acid-Schiff (PAS) staining or other fungal stain of nail clippings; PAS staining can confirm infection and help assess the degree of nail plate involvement.
      • Fungal culture of nail clippings, subungual debris, or desquamated subungual material; culture permits species differentiation but may be limited by cost and result turnaround time.

    Attenuated total-reflectance Fourier transform infrared (ATR-FTIR) spectroscopy is not covered for screening, diagnosis, or confirmation of onychomycosis.

    Testing for the presence of fungal-derived sterols, such as ergosterol, is not covered.

    These tests do not meet coverage criteria because available published scientific literature does not confirm that they are required and beneficial for diagnosing or treating an individual's illness.

    Covered Indications

    Signs of Onychomycosis

    Covered for individuals with signs of onychomycosis when the selected test is one of the following:

    Signs of onychomycosis

    • Covered conventional test

      • Direct microscopic examination with potassium hydroxide.
      • Fungal culture of desquamated subungual material.
      • Fungal stain of a nail clipping or nail clippings.

    Onychomycosis With Infection Unresolved After Antifungal Therapy

    NAAT meets coverage criteria when both of the following are present:

    NAAT coverage circumstance

    Applicable Procedure Codes

    Applicable CPT/HCPCS Procedure CodesCPT
    82542LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed
    87153Culture, typing; identification by nucleic acid sequencing method, each isolate (eg, sequencing of the 16S rRNA gene)
    87205Smear, primary source with interpretation; Gram or Giemsa stain for bacteria, fungi, or cell types
    87206Smear, primary source with interpretation; fluorescent and/or acid fast stain for bacteria, fungi, parasites, viruses or cell types
    87220Tissue examination by KOH slide of samples from skin, hair, or nails for fungi or ectoparasite ova or mites (eg, scabies)
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
    87481Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique
    87482Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification
    1–10 of 16
    1/2

    Provider Guidance and Denial Risks

    Documentation Required

    Confirm Diagnosis and Obtain an Appropriate Nail Specimen

    Confirm suspected onychomycosis with laboratory testing before initiating treatment when clinically appropriate, and obtain an adequate nail specimen to maximize diagnostic accuracy. Clean the nail with 70% isopropyl alcohol; collect subungual debris and approximately 8–10 nail clippings, sampling discolored, dystrophic, brittle, or the most proximal area of onycholysis when accessible.

    • Direct microscopy with potassium hydroxide (KOH) is the preferred rapid, specific, and cost-effective diagnostic method.
    • If KOH is negative but clinical suspicion remains high, consider fungal culture, periodic acid-Schiff (PAS) staining, or other covered confirmatory testing.
    • Trim the nail plate as needed to expose the proximal area of onycholysis; fungal culture may differentiate species, while biopsy with PAS staining can assess nail-plate involvement.
    Denial Risk

    NAAT Limited After Failed Antifungal Therapy

    Clinical Background

    Onychomycosis, also known as tinea unguium, is a fungal infection of the nail caused by dermatophytes, yeasts, or nondermatophyte molds. It accounts for approximately 50% of nail disease cases, and toenails are affected substantially more often than fingernails. Because its clinical findings can resemble noninfectious nail disorders, diagnosis should incorporate both clinical assessment and mycological laboratory results.

    Definitions and Abbreviations

    Definitions
    TermOnychomycosis
    DefinitionA fungal infection of the nail.
    Also known asTinea unguium.
    Definitions
    AbbreviationKOH
    Full termPotassium hydroxide.
    Related preparationPotassium hydroxide preparation with direct microscopy.

    Services Not Meeting Coverage Criteria

    NAAT used to screen for, diagnose, or confirm onychomycosis does not meet coverage criteria unless the individual has onychomycosis and antifungal therapy has failed to resolve the infection.

    ATR-FTIR spectroscopy used to screen for, diagnose, or confirm onychomycosis does not meet coverage criteria.

    Testing for fungal-derived sterols, such as ergosterol, does not meet coverage criteria.

    Policy Summary
    PayerMutual of Omaha
    PolicyOnychomycosis Testing
    Policy CodePolicy N/A
    Change TypeNon-material evidence update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionConfirm suspected onychomycosis with appropriate laboratory testing before initiating treatment.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsApplicable Procedure CodesProvider Guidance and Denial RisksClinical BackgroundDefinitions and AbbreviationsServices Not Meeting Coverage Criteria
  1. Polymerase chain reaction (PCR) or other molecular testing may confirm the diagnosis, but guideline sources describe it as more expensive and not cost-effective for general use.
    • Individual has onychomycosis.
    • Antifungal therapy has failed to resolve the infection.

    Suspected Onychomycosis or Tinea Unguium With Abnormal Nails

    For suspected onychomycosis or tinea unguium involving dystrophic, discolored, brittle, or otherwise abnormal nails, laboratory confirmation is recommended before treatment:

    Suspected fungal nail infection

    • The individual has suspected onychomycosis or tinea unguium, including dystrophic, discolored, brittle, or otherwise abnormal nails.
    • Laboratory confirmation

      • Potassium hydroxide (KOH) preparation with direct microscopy.
      • Fungal culture of nail clippings or subungual debris.
      • Periodic acid-Schiff (PAS) staining or histopathologic examination of nail clippings.
      • Polymerase chain reaction (PCR) or another selected molecular method when clinically appropriate.
    • Timing: Obtain laboratory confirmation before initiating treatment.

    NAAT is covered only for individuals with onychomycosis whose infection has not resolved after antifungal therapy. NAAT used to screen for, diagnose, or confirm onychomycosis outside that failed-therapy indication does not meet coverage criteria.

    • Document the diagnosis and prior antifungal therapy that failed to resolve the infection when billing NAAT.
    • NAAT for initial screening, diagnostic evaluation, or confirmation before documented unresolved infection following antifungal therapy is not covered.
    Denial Risk

    ATR-FTIR Spectroscopy Not Covered

    ATR-FTIR spectroscopy used to screen for, diagnose, or confirm onychomycosis does not meet coverage criteria because published scientific literature is insufficient to establish that the test is required and beneficial for diagnosis and treatment.

    Denial Risk

    Fungal-Derived Sterol Testing Not Covered

    Testing for fungal-derived sterols, including ergosterol, does not meet coverage criteria because published scientific literature is insufficient to establish that the testing is required and beneficial for diagnosis and treatment.

    Definitions
    AbbreviationNAAT
    Full termNucleic acid amplification testing.
    Testing categoryNucleic acid amplification testing is a molecular testing method.
    Definitions
    AbbreviationATR-FTIR
    Full termAttenuated total-reflectance Fourier transform infrared.
    Testing categoryFourier transform infrared spectroscopy using attenuated total reflectance.
    Definitions
    AbbreviationPAS
    Full termPeriodic acid-Schiff.
    Related testPeriodic acid-Schiff staining.
    Definitions
    AbbreviationPCR
    Full termPolymerase chain reaction.
    Testing categoryA nucleic acid amplification method.
    Definitions
    AbbreviationPCR-RFLP
    Full termPolymerase chain reaction-restriction fragment length polymorphism.
    Testing categoryA polymerase chain reaction method involving restriction fragment length polymorphism.
    Definitions
    AbbreviationNGS
    Full termNext-generation sequencing.
    Testing categoryA nucleic acid sequencing method.
    Definitions
    TermOnychomycosis
    DefinitionA fungal nail infection affecting the fingernails or toenails.
    Possible causesRingworm or other fungi, including yeasts.
    Definitions
    TermTinea unguium
    DefinitionA fungal nail infection.
    Also calledOnychomycosis.